<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:08:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7660824" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7660824</identifier>
        <datestamp>2020-11-17</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7660824</article-id>
              <article-id pub-id-type="pmcid">PMC7660824</article-id>
              <article-id pub-id-type="pmc-uid">7660824</article-id>
              <article-id pub-id-type="pmid">32779505</article-id>
              <article-id pub-id-type="pmid">32779505</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.119.016334</article-id>
              <article-id pub-id-type="publisher-id">JAH35420</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Preventive Cardiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers</article-title>
              </title-group>
              <contrib-group>
                <contrib id="jah35420-cr-0001" contrib-type="author">
                  <name>
                    <surname>Climax</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>PhD, DSc</degrees>
                  <xref ref-type="aff" rid="jah35420-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah35420-note-1002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0002" contrib-type="author">
                  <name>
                    <surname>Newsome</surname>
                    <given-names>Philip N.</given-names>
                  </name>
                  <degrees>MBChB, PhD</degrees>
                  <xref ref-type="aff" rid="jah35420-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35420-aff-0003">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35420-aff-0004">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="jah35420-note-1002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0003" contrib-type="author">
                  <name>
                    <surname>Hamza</surname>
                    <given-names>Moayed</given-names>
                  </name>
                  <degrees>MBBCh</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4139-2464</contrib-id>
                  <xref ref-type="aff" rid="jah35420-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0004" contrib-type="author">
                  <name>
                    <surname>Weissbach</surname>
                    <given-names>Markus</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah35420-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0005" contrib-type="author">
                  <name>
                    <surname>Coughlan</surname>
                    <given-names>David</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35420-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0006" contrib-type="author">
                  <name>
                    <surname>Sattar</surname>
                    <given-names>Naveed</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1604-2593</contrib-id>
                  <xref ref-type="aff" rid="jah35420-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0007" contrib-type="author">
                  <name>
                    <surname>McGuire</surname>
                    <given-names>Darren K.</given-names>
                  </name>
                  <degrees>MD, MHSc</degrees>
                  <xref ref-type="aff" rid="jah35420-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah35420-cr-0008" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Bhatt</surname>
                    <given-names>Deepak L.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1278-6245</contrib-id>
                  <xref ref-type="aff" rid="jah35420-aff-0007">
                    <sup>7</sup>
                  </xref>
                  <address>
                    <email>dlbhattmd@post.harvard.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah35420-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>Afimmune</institution>
                <city>Dublin</city>
                <country country="IE">Ireland</country>
              </aff>
              <aff id="jah35420-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35420-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Liver and Gastrointestinal Research</named-content>
                <named-content content-type="organisation-division">Institute of Immunology and Immunotherapy</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35420-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Liver Unit</named-content>
                <institution>University Hospitals Birmingham NHS Foundation Trust</institution>
                <city>Birmingham</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35420-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Institute of Cardiovascular and Medical Sciences</named-content>
                <institution>University of Glasgow</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35420-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>University of Texas Southwestern Medical Center</institution>
                <city>Dallas</city>
                <named-content content-type="country-part">TX</named-content>
              </aff>
              <aff id="jah35420-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>Brigham and Women’s Hospital Heart &amp; Vascular Center</institution>
                <institution>Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence to: Deepak L. Bhatt, MD, MPH, Brigham and Women's Hospital Heart &amp; Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115. E‐mail: <email>dlbhattmd@post.harvard.edu</email></corresp>
                <fn id="jah35420-note-1002">
                  <label>†</label>
                  <p>Dr Climax and Prof. Newsome are co‐first authors.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>18</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>16</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.16</issue-id>
              <elocation-id>e016334</elocation-id>
              <history>
                <date date-type="received">
                  <day>11</day>
                  <month>3</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. </copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e016334.pdf"/>
              <abstract id="jah35420-abs-0001">
                <sec id="jah35420-sec-0001">
                  <title>Background</title>
                  <p>Epeleuton is 15‐hydroxy eicosapentaenoic acid ethyl ester, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid. The primary objective was to assess the effect of epeleuton on markers of nonalcoholic fatty liver disease (NAFLD) with post hoc analyses of cardiometabolic markers.</p>
                </sec>
                <sec id="jah35420-sec-0002">
                  <title>Methods and Results</title>
                  <p>In a multicenter, randomized, double‐blind, placebo‐controlled trial, 96 adults with nonalcoholic fatty liver disease and body mass index 25 to 40 were randomized in a 1:1:1 ratio to receive epeleuton 2 g/day, epeleuton 1 g/day, or placebo for 16 weeks. A total of 27% of patients had diabetes mellitus. Primary end points of changes in alanine aminotransferase and liver stiffness did not improve at week 16. Secondary and post hoc analyses investigated changes in cardiometabolic markers. Epeleuton 2 g/day significantly decreased triglycerides, very‐low‐density lipoprotein cholesterol, and total cholesterol without increasing low‐density lipoprotein cholesterol. Despite a low mean baseline hemoglobin A1C (HbA<sub>1C</sub>; 6.3±1.3%), epeleuton 2 g/day significantly decreased HbA<sub>1c</sub> (−0.4%; <italic>P</italic>=0.026). Among patients with baseline HbA<sub>1c</sub> &gt;6.5%, epeleuton 2 g/day decreased HbA<sub>1c</sub> by 1.1% (<italic>P</italic>=0.047; n=26). Consistent dose‐dependent reductions were observed for fasting plasma glucose, insulin, and insulin resistance indices. Epeleuton 2 g/day decreased circulating markers of cardiovascular risk and endothelial dysfunction. Epeleuton was well tolerated, with a safety profile not different from placebo.</p>
                </sec>
                <sec id="jah35420-sec-0003">
                  <title>Conclusions</title>
                  <p>While epeleuton did not meet its primary end points on alanine aminotransferase or liver stiffness, it significantly decreased triglycerides, HbA<sub>1C</sub>, plasma glucose, and inflammatory markers. These data suggest epeleuton may have potential for cardiovascular risk reduction and nonalcoholic fatty liver disease by simultaneously targeting hypertriglyceridemia, hyperglycemia, and systemic inflammation. Further trials are planned.</p>
                </sec>
                <sec id="jah35420-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clini​caltr​ials.gov</ext-link>; Unique identifier: NCT02941549.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah35420-kwd-0001">15‐HEPE</kwd>
                <kwd id="jah35420-kwd-0002">DS102</kwd>
                <kwd id="jah35420-kwd-0003">epeleuton</kwd>
                <kwd id="jah35420-kwd-0004">n‐3 fatty acid</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Clinical Studies</kwd>
                <kwd>Inflammation</kwd>
                <kwd>Lipids and Cholesterol</kwd>
                <kwd>Cardiovascular Disease</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Afimmune</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>National Institute of Health Research (NIHR) Birmingham Biomedical Research Centre (BRC)</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="4"/>
                <page-count count="16"/>
                <word-count count="9391"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>18-August 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.1 mode:remove_FC converted:29.09.2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah35420-cit-1001"><source xml:lang="en">J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>e016334</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.119.016334</pub-id>.<pub-id pub-id-type="pmid">32779505</pub-id></mixed-citation>
              </p>
              <fn-group id="jah35420-ntgp-0001">
                <fn id="jah35420-note-1001">
                  <p>Supplementary Materials for this article are available at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.016334">https://www.ahajo​urnals.org/doi/suppl/​10.1161/JAHA.119.016334</ext-link>
</p>
                </fn>
                <fn id="jah35420-note-1003">
                  <p>For Sources of Funding and Disclosures, see page 15.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah35420-body-0001">
            <def-list list-content="abbreviations" id="jah35420-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>15(S)‐HEPE</term>
                <def>
                  <p>15‐hydroxy eicosapentaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>Adipo‐IR</term>
                <def>
                  <p>adipose insulin resistance</p>
                </def>
              </def-item>
              <def-item>
                <term>AE</term>
                <def>
                  <p>adverse event</p>
                </def>
              </def-item>
              <def-item>
                <term>ALT</term>
                <def>
                  <p>alanine aminotransferase</p>
                </def>
              </def-item>
              <def-item>
                <term>BMI</term>
                <def>
                  <p>body mass index</p>
                </def>
              </def-item>
              <def-item>
                <term>EPA</term>
                <def>
                  <p>eicosapentaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>HbA<sub>1C</sub></term>
                <def>
                  <p>hemoglobin A<sub>1C</sub>
</p>
                </def>
              </def-item>
              <def-item>
                <term>HDL‐C</term>
                <def>
                  <p>high‐density lipoprotein cholesterol</p>
                </def>
              </def-item>
              <def-item>
                <term>HOMA‐IR</term>
                <def>
                  <p>homeostatic model assessment for insulin resistance</p>
                </def>
              </def-item>
              <def-item>
                <term>hsCRP</term>
                <def>
                  <p>high‐sensitivity C‐reactive protein</p>
                </def>
              </def-item>
              <def-item>
                <term>LDL‐C</term>
                <def>
                  <p>low‐density lipoprotein cholesterol</p>
                </def>
              </def-item>
              <def-item>
                <term>mITT</term>
                <def>
                  <p>modified intention‐to-treat</p>
                </def>
              </def-item>
              <def-item>
                <term>NAFLD</term>
                <def>
                  <p>nonalcoholic fatty liver disease</p>
                </def>
              </def-item>
              <def-item>
                <term>RLP‐C</term>
                <def>
                  <p>remnant lipoprotein cholesterol</p>
                </def>
              </def-item>
              <def-item>
                <term>VLDL‐C</term>
                <def>
                  <p>very-low‐density lipoprotein cholesterol</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah35420-blkfxd-0001" orientation="portrait">
                <sec id="jah35420-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah35420-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah35420-list-0001">
                        <list-item>
                          <p>In this phase IIa randomized, double‐blind, placebo‐controlled trial, epeleuton, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid, did not decrease the primary end points, liver stiffness, or alanine aminotransferase levels in patients with obesity and nonalcoholic fatty liver disease.</p>
                        </list-item>
                        <list-item>
                          <p>Post hoc analysis revealed hypothesis‐generating findings that epeleuton decreased triglycerides, inflammatory markers, insulin resistance indices, and meaningfully decreased hemoglobin A<sub>1C</sub>, a novel finding for an n‐3 fatty acid.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah35420-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah35420-list-0002">
                        <list-item>
                          <p>Future trials will be necessary to determine whether epeleuton may have meaningful potential for cardiovascular risk reduction and nonalcoholic fatty liver disease by simultaneously targeting hypertriglyceridemia, hyperglycemia, and systemic inflammation, and to assess the full therapeutic potential of epeleuton.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah35420-sec-0009">
              <p>Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of liver disease globally and results from the buildup of fat within the liver commonly in the setting of weight gain and insulin resistance.<xref rid="jah35420-bib-0001" ref-type="ref"><sup>1</sup></xref> There are no approved therapies for the treatment of NAFLD, and thus patients can suffer from progressive liver fibrosis and decompensation. Alongside the development of liver disease, many patients with NAFLD are at increased risk of type 2 diabetes mellitus, dyslipidemia, chronic kidney disease, and cardiovascular disease.<xref rid="jah35420-bib-0001" ref-type="ref"><sup>1</sup></xref> Indeed, cardiovascular disease remains the leading cause of morbidity and mortality globally, with persistently high rates of ischemic events reported in many populations.<xref rid="jah35420-bib-0002" ref-type="ref"><sup>2</sup></xref>
</p>
              <p>Despite the prevalent use of statins; blood pressure control; and therapeutic counseling for smoking abstinence, weight management, and physical activity, ischemic heart disease remains the leading cause of premature adult mortality worldwide.<xref rid="jah35420-bib-0003" ref-type="ref"><sup>3</sup></xref> Recent advances in primary and secondary prevention of cardiovascular events provide hope that new therapies targeting various cardiovascular risk factors including elevated triglycerides, inflammation, and hyperglycemia will produce benefits additional to current prevention strategies including low‐density lipoprotein cholesterol (LDL‐C) management with statins.<xref rid="jah35420-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35420-bib-0007" ref-type="ref"><sup>7</sup></xref> While the novel glucose‐lowering medications for patients with type 2 diabetes mellitus may lessen cardiovascular risk largely independent of glucose lowering per se, there is evidence for cardiovascular benefits of glucose lowering, and Mendelian randomization studies support this.<xref rid="jah35420-bib-0008" ref-type="ref"><sup>8</sup></xref>, <xref rid="jah35420-bib-0009" ref-type="ref"><sup>9</sup></xref>, <xref rid="jah35420-bib-0010" ref-type="ref"><sup>10</sup></xref>
</p>
              <p>Results from the JELIS (Japan Eicosapentaenoic Acid Lipid Intervention Study) and the REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) demonstrated superior cardiovascular outcomes with the experimental intervention. In addition, complementary results from several recent epidemiologic and Mendelian randomization studies have advanced treatment of hypertriglyceridemia specifically with higher‐dose eicosapentaenoic acid (EPA) as a potential paradigm for cardiovascular risk reduction.<xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0011" ref-type="ref"><sup>11</sup></xref>, <xref rid="jah35420-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35420-bib-0013" ref-type="ref"><sup>13</sup></xref>, <xref rid="jah35420-bib-0014" ref-type="ref"><sup>14</sup></xref>, <xref rid="jah35420-bib-0015" ref-type="ref"><sup>15</sup></xref> Indeed, in the primary analyses of the aforementioned trials, the risk of major adverse cardiovascular events was reduced by 19% and 25%, respectively, compared with the control arms following treatment with EPA's ethyl ester, icosapent ethyl, in patients on optimized statin therapy.<xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0011" ref-type="ref"><sup>11</sup></xref> These findings contrast with results from other medications that reduce triglycerides, including low‐dose n‐3 fatty acid combination products (EPA plus docosahexaenoic acid), fibrates, and niacin, where reductions in cardiovascular events have not been significant in the statin era.<xref rid="jah35420-bib-0016" ref-type="ref"><sup>16</sup></xref>, <xref rid="jah35420-bib-0017" ref-type="ref"><sup>17</sup></xref> Cumulatively, this may suggest that the JELIS and REDUCE‐IT studies do not establish a purely triglyceride‐based paradigm for cardiovascular risk reduction but instead support specific cardiovascular benefits of actions at the EPA axis.</p>
              <p>Similarly, recent cardiovascular outcome trials of antihyperglycemic medications have shown that in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease, antihyperglycemic agents can reduce the risk of future cardiovascular events.<xref rid="jah35420-bib-0018" ref-type="ref"><sup>18</sup></xref>, <xref rid="jah35420-bib-0019" ref-type="ref"><sup>19</sup></xref>, <xref rid="jah35420-bib-0020" ref-type="ref"><sup>20</sup></xref> Glucagon‐like peptide 1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors have emerged as therapeutic classes that significantly reduce the risk of major adverse cardiovascular events in secondary prevention cohorts.<xref rid="jah35420-bib-0004" ref-type="ref"><sup>4</sup></xref> However, a recent meta‐analysis did not show similar favorable effects of sodium‐glucose cotransporter‐2 inhibitors for primary prevention of ischemic events in patients without established atherosclerotic cardiovascular disease.<xref rid="jah35420-bib-0021" ref-type="ref"><sup>21</sup></xref> Furthermore, cardiovascular outcome trials of dipeptidyl peptidase 4 inhibitors have not shown any cardiovascular benefits.<xref rid="jah35420-bib-0022" ref-type="ref"><sup>22</sup></xref> Together, these results indicate that new antihyperglycemic agents that have additional cardiovascular benefits may provide incremental improvements in outcomes compared with current antihyperglycemic therapeutic classes.</p>
              <p>Epeleuton is 15‐hydroxy eicosapentaenoic acid (15(S)‐HEPE) ethyl ester, a second‐generation synthetic n‐3 fatty acid derivative of EPA. 15(S)‐HEPE, at much lower concentrations, is an endogenous downstream 15‐lipoxygenase metabolite of EPA that has been associated with potent anti‐inflammatory and antiproliferative effects in nonclinical studies.<xref rid="jah35420-bib-0023" ref-type="ref"><sup>23</sup></xref>, <xref rid="jah35420-bib-0024" ref-type="ref"><sup>24</sup></xref> The therapeutic effects of 15(S)‐HEPE are thought to be induced by pleiotropic modes of action. We postulated that because of the expected increase in fatty acid oxidation and basal metabolic rate following n‐3 fatty acid treatment,<xref rid="jah35420-bib-0025" ref-type="ref"><sup>25</sup></xref> and the observed improvement of NAFLD histology, hepatic fat content, alanine aminotransferase (ALT) and markers of fibrosis in preclinical testing, epeleuton may exert a beneficial treatment effect in patients with NAFLD.</p>
              <p>This phase 2a trial was designed to investigate the efficacy and safety of 2 doses of epeleuton; 1 and 2 g/day compared with placebo in patients with NAFLD, a body mass index (BMI) between 25.0 and 40.0 kg/m<sup>2</sup>, and elevated serum ALT. Because of the high prevalence of metabolic syndrome, type 2 diabetes mellitus, and dyslipidemia in patients with NAFLD,<xref rid="jah35420-bib-0001" ref-type="ref"><sup>1</sup></xref> secondary and post hoc analyses were undertaken to compare the lipid‐lowering, antihyperglycemic, and anti‐inflammatory effects of epeleuton 1 g/day and epeleuton 2 g/day with placebo. On the basis of nonclinical pharmacology studies, we hypothesized that epeleuton may exert superior triglyceride‐lowering and anti‐inflammatory effects than its endogenous precursor EPA and may provide additional therapeutic benefits attributable to its distinct chemical structure.</p>
            </sec>
            <sec sec-type="methods" id="jah35420-sec-0010">
              <title>METHODS</title>
              <sec id="jah35420-sec-0011">
                <title>Study Design and Oversight</title>
                <p>The data that support the findings of this study may be made available from the corresponding author upon reasonable request. This was a 16‐week, multicenter, international, randomized, double‐blind, placebo‐controlled, phase 2a trial (NCT02941549) of epeleuton in patients with NAFLD and elevated BMI. The trial was approved by the central and local institutional review boards or ethics committees and was conducted according to the provisions of the International Conference on Harmonization for Good Clinical Practice, the World Health Organization Declaration of Helsinki, and all applicable regulatory requirements. All participants provided written informed consent before participation in the trial.</p>
              </sec>
              <sec id="jah35420-sec-0012">
                <title>Study Participants and Study Conduct</title>
                <p>Patients were assigned to trial treatment in accordance with the randomization schedule in permuted blocks stratified according to trial site. Patients meeting all inclusion and no exclusion criteria were randomized in a 1:1:1 ratio to epeleuton 2 g/day (epeleuton 1 g twice daily), epeleuton 1 g/day (epeleuton 500 mg twice daily) or placebo (light liquid paraffin) twice daily.</p>
                <p>Eligibility criteria at screening included an age of 18 to 75 years, NAFLD based on the presence of hepatic steatosis on imaging or histology in the absence of secondary causes, BMI between 25.0 and 40.0 kg/m<sup>2</sup>, and ALT ≥1.5 times the upper limit of normal and &lt;5 times upper limit of normal. Exclusion criteria included weight change &gt;5% in the 3 months before screening, history of gastric bypass surgery, history of or scheduled orthotopic liver transplant, hemoglobin A1C (HbA<sub>1c</sub>) ≥9%, decompensated or severe liver disease, or patients requiring antihyperglycemic treatment or lipid‐lowering treatment who were not on a stable dose for at least 3 months before screening. Patients were excluded from the trial if they used dietary supplements containing n‐3 or n‐6 fatty acids in the 4 weeks before baseline. Detailed inclusion and exclusion criteria are provided in Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
              </sec>
              <sec id="jah35420-sec-0013">
                <title>End Points</title>
                <p>The primary end points were changes from baseline to week 16 in ALT and liver stiffness as measured by transient elastography. This was the first clinical trial of epeleuton in this patient population. A sample size of 32 participants per group was estimated to provide 80% power for each of the primary end points, assuming a 20% difference in the percentage change between each epeleuton treatment group and placebo, a standard deviation of 25%, a 2‐sided alpha rate of 0.05 and accounting for a 20% dropout rate. ALT was assessed at baseline and weeks 2, 4, 8, 12, 16, and the week 20 posttreatment follow‐up visit. Liver stiffness was assessed at baseline and week 16.</p>
                <p>Changes from baseline of hepatic fat as measured by the controlled attenuation parameter,<xref rid="jah35420-bib-0026" ref-type="ref"><sup>26</sup></xref> an ultrasound‐based method for hepatic steatosis measurement, measured at baseline and week 16; homeostatic model assessment for insulin resistance (HOMA‐IR),<xref rid="jah35420-bib-0027" ref-type="ref"><sup>27</sup></xref> a surrogate measure of β‐cell function and insulin resistance based on fasting plasma glucose and insulin, measured at baseline and weeks 2, 4, 8, 12, 16, and 20; and adipose insulin resistance (Adipo‐IR),<xref rid="jah35420-bib-0028" ref-type="ref"><sup>28</sup></xref> a measure of impaired suppression of lipolysis in the presence of high insulin levels that has been associated with impaired glucose tolerance and elevated plasma free fatty acid levels, measured at baseline and weeks 2, 4, 8, 12, 16, and 20, were assessed as secondary end points.</p>
                <p>Lipid and glycemic values were initially measured as safety parameters in the study at baseline and weeks 2, 4, 8, 12, 16, and 20. Post hoc analyses assessed percentage changes from baseline to week 16 of triglycerides, very‐low‐density lipoprotein cholesterol (VLDL‐C), non–high‐density lipoprotein cholesterol (HDL‐C), total cholesterol, HDL‐C, low‐density lipoprotein cholesterol (LDL‐C), and remnant lipoprotein cholesterol (RLP‐C). Non–HDL‐C was calculated by subtracting HDL‐C from total cholesterol. RLP‐C was derived by subtracting LDL‐C from non–HDL‐C. Changes from baseline of HbA<sub>1c</sub>, fasting plasma glucose, insulin, free fatty acids, and hsCRP (high‐sensitivity C‐reactive protein) were also assessed.</p>
                <p>High‐throughput ultrasensitive serum proteomic analyses (OLINK proximity extension assay platform)<xref rid="jah35420-bib-0029" ref-type="ref"><sup>29</sup></xref> were performed to quantify changes from baseline to week 16 of a panel of 364 circulating biomarkers associated with systemic inflammation, fibrosis, endothelial dysfunction, cardiovascular risk, and other biological processes. Analytes and bioanalytical laboratories are detailed in Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S2</xref>.</p>
                <p>Blood samples for trough plasma total and unesterified 15(S)‐HEPE concentrations were collected via direct venipuncture before the first daily dose at baseline; during treatment weeks 2, 4, 8, and 16; and at the week 20 posttreatment follow‐up. Plasma unesterified and total 15(S)‐HEPE concentrations were determined by Charles River Laboratories (Edinburgh) using a validated liquid chromatography–tandem mass spectrometry method.</p>
              </sec>
              <sec id="jah35420-sec-0014">
                <title>Statistical Analysis</title>
                <p>The primary population for efficacy analyses was a modified intention‐to‐treat (mITT) population that consisted of all randomized patients who received at least 1 dose of the study drug and had 1 postbaseline measurement. The safety population consisted of all patients who received at least 1 dose of the study drug.</p>
                <p>The primary end points ALT and liver stiffness, and the prespecified secondary end points hepatic fat measured by controlled attenuation parameter, HOMA‐IR, and Adipo‐IR at each visit were analyzed using a mixed model of repeated measures under missing‐at‐random assumptions. The mixed model of repeated measures included treatment group, visit, and treatment‐by‐visit interaction as fixed effects and baseline as well as treatment‐by‐baseline as interaction terms. Least squares means and corresponding 95% CIs for each treatment group, along with overall and pair‐wise <italic>P</italic> values were calculated. A 2‐sided <italic>P</italic>&lt;0.05 was considered statistically significant for all comparisons.</p>
                <p>Analysis of changes in triglycerides, non–HDL‐C, VLDL‐C, LDL‐C, HDL‐C, total cholesterol, and RLP‐C were performed using a Wilcoxon rank sum test with the Hodges‐Lehmann median and 95% CIs. The Wilcoxon rank‐sum test was selected as a nonparametric test that is robust against outliers.</p>
                <p>Changes from baseline of HbA<sub>1c</sub>, fasting plasma glucose, insulin, and hsCRP were analyzed using an ANCOVA model with baseline value as a covariate. The proportion of patients with elevated HbA<sub>1C</sub> that normalized at end of treatment was analyzed using logistic regression with baseline HbA<sub>1C</sub> as a covariate. A nonparametric ANCOVA model was applied to fasting plasma glucose and insulin because of the presence of outliers.</p>
                <p>For analysis of serum proteomics, normalized protein expression values were modeled using a linear mixed effects model with visit, treatment, and the interaction between them as fixed effects and a random intercept for each patient. Post hoc contrasts were used to estimate the changes with treatment within each treatment group. <italic>P</italic> values of serum proteomics were adjusted for multiple testing using the Benjamini–Hochberg procedure,<xref rid="jah35420-bib-0030" ref-type="ref"><sup>30</sup></xref> which controls for false discovery rate.</p>
                <p>For all efficacy end points, a hierarchical closed testing procedure was used for comparing each of the epeleuton treatment groups with placebo. Epeleuton 2 g/day versus placebo was tested first. If the test was not significant, the comparison of epeleuton 1 g/day versus placebo was not considered eligible for declaring significance even if the <italic>P</italic> value was &lt;0.05. A pairwise comparison of epeleuton 2 g versus epeleuton 1 g was also conducted and considered as descriptive. No statistical testing of adverse event rates was performed. Analysis of adverse event rates was descriptive.</p>
                <p>Statistical analyses of the primary and secondary end points were conducted using SAS Version 9.2 or above. Post hoc analyses were conducted using SAS JMP Version 14.2.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah35420-sec-0015">
              <title>Results</title>
              <sec id="jah35420-sec-0016">
                <title>Patient Population</title>
                <p>Between December 2016 and January 2019, a total of 96 patients were enrolled and randomized in permuted blocks of 3 to each of the treatment groups. A total of 33 patients were randomly assigned to epeleuton 2 g/day, 32 to epeleuton 1 g/day, and 31 to placebo. Patient disposition including the numbers of patients who were screened, randomized to a treatment group, and included in the mITT population are shown in the Consolidated Standards of Reporting Trials flow diagram in Figure <xref rid="jah35420-fig-0001" ref-type="fig">1</xref>.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35420-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <title>Consolidated Standards of Reporting Trials flow diagram of subject disposition.</title>
                    <p>mITT indicates modified intention‐to‐treat.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e016334-g001"/>
                </fig>
                <p>Baseline patient characteristics of the mITT population are listed in Table <xref rid="jah35420-tbl-0001" ref-type="table">1</xref>. Serum ALT and liver stiffness were higher at baseline in the placebo group, triglycerides were higher in the epeleuton 2 g/day group. Baseline characteristics were otherwise comparable across treatment groups. Median ALT concentrations at baseline were 74.0, 70.5, and 96.5 U/L in the epeleuton 2 g/day, epeleuton 1 g/day, and placebo groups, respectively. Median liver stiffness was 7.90, 8.16, and 8.42 kPa in the epeleuton 2 g/day, epeleuton 1 g/day, and placebo groups, respectively. Median triglyceride levels were 242.0, 146.0, and 150.0 mg/dL in the epeleuton 2 g/day, epeleuton 1 g/day, and placebo groups, respectively. Median LDL‐C levels were 133.0, 133.0, and 138.5 mg/dL in the epeleuton 2 g/day, epeleuton 1 g/day, and placebo groups, respectively. Most (88.2%) patients were not on statin therapy before screening. Baseline HbA<sub>1c</sub> (%) and fasting plasma glucose were comparable across the treatment groups. Mean HbA<sub>1c</sub> at baseline was 6.2%; 28.0% of patients had an HbA<sub>1c</sub> &gt;6.5% at baseline, and 18.3% of patients had a HbA<sub>1c</sub> &gt;7.0% at baseline; and 25.8% of trial participants were on antihyperglycemic medications.</p>
                <table-wrap id="jah35420-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Patient Characteristics (mITT Population)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1">Epeleuton 2 g/d</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Epeleuton 1 g/d</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Placebo</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Characteristic</td>
                        <td align="left" rowspan="1" colspan="1">(N=31)</td>
                        <td align="left" rowspan="1" colspan="1">(N=32)</td>
                        <td align="left" rowspan="1" colspan="1">(N=30)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Sex, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">10 (32.3)</td>
                        <td align="left" rowspan="1" colspan="1">12 (37.5)</td>
                        <td align="left" rowspan="1" colspan="1">9 (30.0)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Age, y</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">45.7 (12.0)</td>
                        <td align="left" rowspan="1" colspan="1">50.8 (13.7)</td>
                        <td align="left" rowspan="1" colspan="1">48.8 (11.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Race, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">31 (100.00)</td>
                        <td align="left" rowspan="1" colspan="1">30 (93.75)</td>
                        <td align="left" rowspan="1" colspan="1">27 (90.00)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.00)</td>
                        <td align="left" rowspan="1" colspan="1">2 (6.25)</td>
                        <td align="left" rowspan="1" colspan="1">3 (10.00)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Weight, kg</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">95.0 (17.8)</td>
                        <td align="left" rowspan="1" colspan="1">98.3 (19.3)</td>
                        <td align="left" rowspan="1" colspan="1">101.2 (16.4)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">31.6 (3.6)</td>
                        <td align="left" rowspan="1" colspan="1">33.4 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">33.4 (4.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (29.0)</td>
                        <td align="left" rowspan="1" colspan="1">8 (25.0)</td>
                        <td align="left" rowspan="1" colspan="1">8 (26.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Alanine aminotransferase, U/L</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">74.0 (40.0)</td>
                        <td align="left" rowspan="1" colspan="1">70.5 (46.0)</td>
                        <td align="left" rowspan="1" colspan="1">96.5 (45.0)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Liver stiffness, kPa</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">7.90 (5.4)</td>
                        <td align="left" rowspan="1" colspan="1">8.16 (3.2)</td>
                        <td align="left" rowspan="1" colspan="1">8.42 (4.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">HbA<sub>1c</sub> (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">6.3 (1.31)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (1.29)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (1.02)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HbA<sub>1c</sub> &gt;6.5%, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (32.3)</td>
                        <td align="left" rowspan="1" colspan="1">9 (28.1)</td>
                        <td align="left" rowspan="1" colspan="1">8 (26.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HbA<sub>1c</sub> &gt;7.0%, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (19.4)</td>
                        <td align="left" rowspan="1" colspan="1">6 (18.8)</td>
                        <td align="left" rowspan="1" colspan="1">5 (16.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Fasting plasma glucose, mg/dL</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">119.1 (42.8)</td>
                        <td align="left" rowspan="1" colspan="1">110.9 (29.9)</td>
                        <td align="left" rowspan="1" colspan="1">120.3 (40.2)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Triglycerides, mg/dL</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">242.0 (155.0)</td>
                        <td align="left" rowspan="1" colspan="1">146.0 (122.3)</td>
                        <td align="left" rowspan="1" colspan="1">150.0 (94.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">LDL cholesterol, mg/dL</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">133.0 (49.0)</td>
                        <td align="left" rowspan="1" colspan="1">133.0 (59.5)</td>
                        <td align="left" rowspan="1" colspan="1">138.5 (59.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Statin use, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (9.7)</td>
                        <td align="left" rowspan="1" colspan="1">4 (12.5)</td>
                        <td align="left" rowspan="1" colspan="1">4 (13.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Antihyperglycemic use, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (25.8)</td>
                        <td align="left" rowspan="1" colspan="1">9 (28.1)</td>
                        <td align="left" rowspan="1" colspan="1">7 (23.3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah35420-ntgp-0002">
                    <fn id="jah35420-note-0004">
                      <p>HbA<sub>1c</sub> indicates hemoglobin A<sub>1C</sub>; IQR, interquartile range; and LDL, low‐density lipoprotein.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah35420-sec-0017">
                <title>Primary and Secondary End Points</title>
                <p>Treatment with epeleuton at 1 and 2 g/day doses did not result in improvements of the primary end points of serum ALT and liver stiffness at week 16 compared with placebo (Table <xref rid="jah35420-tbl-0002" ref-type="table">2</xref>). A decrease from baseline was observed in all treatment groups for both ALT and liver stiffness, reaching significance in the placebo group (ALT, <italic>P</italic>=0.0008; liver stiffness, <italic>P</italic>=0.0003) where higher median baseline concentrations were observed (Table <xref rid="jah35420-tbl-0001" ref-type="table">1</xref>). ALT decreased by 6.9, 10.1, and 16.3 U/L in the epeleuton 1 g/day, epeleuton 2 g/day, and placebo groups, respectively. Liver stiffness decreased by 1.3, 0.7, and 2.2 kPa in the epeleuton 1 g/day, epeleuton 2 g/day, and placebo groups, respectively.</p>
                <table-wrap id="jah35420-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Change in ALT, Liver Stiffness, and Hepatic Fat</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton</th>
                        <th align="center" rowspan="2" colspan="2" valign="top">Placebo (n=30)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 2 g/d (n=31)</th>
                        <th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 1 g/d (n=32)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>(vs Placebo)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>(vs Placebo)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ALT, U/L</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>93.3</p>
                          <p>(47.6)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−10.1</p>
                          <p>(−36.9, 16.8)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic>=0.0737</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.7309</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>82.7</p>
                          <p>(33.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−6.9</p>
                          <p>(−34.5, 20.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic>=0.7347</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.5946</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>98.1</p>
                          <p>(35.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−16.3</p>
                          <p>(−44.2, 11.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic> =0.0008</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Liver stiffness, kPa</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>8.99</p>
                          <p>(6.74)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−0.73</p>
                          <p>(−1.55, 0.10)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic>=0.1165</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0058</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>8.53</p>
                          <p>(3.50)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−1.31</p>
                          <p>(−2.11, −0.51)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic> =0.0038</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0763</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>9.10</p>
                          <p>(4.12)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−2.23</p>
                          <p>(−3.07, −1.38)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic> =0.0003</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hepatic fat measured by CAP, dB/m</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>327.8</p>
                          <p>(31.7)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−22.4</p>
                          <p>(−43.0, −1.8)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic> =0.0093</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.4593</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>310.3</p>
                          <p>(49.5)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−16.3</p>
                          <p>(−36.8, 4.1)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic>=0.083</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.7671</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>332.9</p>
                          <p>(43.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−12.3</p>
                          <p>(−34.4, 9.9)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0006">*</xref><italic>P</italic> =0.0106</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah35420-ntgp-0003">
                    <fn id="jah35420-note-0005">
                      <p>ALT indicates alanine aminotransferase; CAP, controlled attenuation parameter; and LS, least squares.</p>
                    </fn>
                    <fn id="jah35420-note-0006">
                      <label>a</label>
                      <p>Indicates <italic>P</italic> value of within‐group change from baseline.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Analysis of subgroups with BMI &gt;30 and BMI &lt;30 was generally consistent with the mITT analysis for liver stiffness. Among patients with baseline BMI &lt;30, epeleuton 1 and 2 g/day‐treated patients had higher ALT concentrations at baseline and numerically greater reductions than placebo. Conversely, placebo‐treated patients had higher baseline ALT concentrations in the subgroup with BMI &gt;30 and exhibited numerically greater reductions suggesting that changes in ALT were dependent on baseline concentrations (Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
                <p>Treatment with epeleuton produced a dose‐dependent reduction of hepatic fat assessed by controlled attenuation parameter, greatest in the epeleuton 2 g/day group but the between‐group comparison did not reach significance at the week 16 end‐of‐treatment visit. Hepatic fat decreased by 16.3, 22.4, and 12.3 U/L in the epeleuton 1 g/day, epeleuton 2 g/day, and placebo groups, respectively (Table <xref rid="jah35420-tbl-0002" ref-type="table">2</xref>).</p>
                <p>In a dose‐dependent manner, HOMA‐IR improved compared with placebo. Epeleuton 2 g/day reduced least squares mean HOMA‐IR significantly compared with placebo (epeleuton 2 g/day –2.04 points versus placebo −0.39 points; <italic>P</italic>=0.006) (Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="jah35420-fig-0002" ref-type="fig">2</xref>). A similar pattern of dose‐dependent improvement was observed for Adipo‐IR. Epeleuton 2 g/day induced a statistically significant least squares mean decrease of Adipo‐IR compared with placebo (epeleuton 2 g/day −21.07 points versus placebo +3.66 points; <italic>P</italic>=0.017) (Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="jah35420-fig-0002" ref-type="fig">2</xref>).</p>
                <table-wrap id="jah35420-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Change in HbA<sub>1c</sub>, Glycemic Parameters, Insulin Resistance Parameters, and hsCRP</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="center" colspan="7" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton</th>
                        <th align="center" rowspan="2" colspan="2" valign="top">Placebo (n=30)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 2 g/d (n=31)</th>
                        <th align="center" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 1 g/d (n=32)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>(vs Placebo)</p>
                        </th>
                        <th align="center" colspan="2" valign="top" rowspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>(vs Placebo)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>Mean (SD)</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HbA1c (%)</td>
                        <td align="left" rowspan="1" colspan="1">6.3 (1.31)</td>
                        <td align="left" rowspan="1" colspan="1">−0.42 (0.75)</td>
                        <td align="left" rowspan="1" colspan="1">0.0255</td>
                        <td align="left" colspan="2" rowspan="1">6.2 (1.29)</td>
                        <td align="left" rowspan="1" colspan="1">−0.10 (0.49)</td>
                        <td align="left" rowspan="1" colspan="1">0.6827</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (1.02)</td>
                        <td align="left" rowspan="1" colspan="1">−0.08 (0.44)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Subgroups</td>
                        <td align="left" colspan="9" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HbA<sub>1c</sub> (%) &gt;6.5%</td>
                        <td align="left" rowspan="1" colspan="1">7.9 (1.03) n=10</td>
                        <td align="left" rowspan="1" colspan="1">−1.13 (0.91)</td>
                        <td align="left" rowspan="1" colspan="1">0.0474</td>
                        <td align="left" colspan="2" rowspan="1">7.8 (1.25) n=9</td>
                        <td align="left" rowspan="1" colspan="1">−0.33 (0.84)</td>
                        <td align="left" rowspan="1" colspan="1">0.8523</td>
                        <td align="left" rowspan="1" colspan="1">7.6 (0.75) n==8</td>
                        <td align="left" rowspan="1" colspan="1">−0.26 (0.66)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HbA<sub>1c</sub> (%) &gt;7.0%</td>
                        <td align="left" rowspan="1" colspan="1">8.6 (0.55) n=6</td>
                        <td align="left" rowspan="1" colspan="1">−1.30 (1.06)</td>
                        <td align="left" rowspan="1" colspan="1">0.1044</td>
                        <td align="left" colspan="2" rowspan="1">8.4 (1.1) n=6</td>
                        <td align="left" rowspan="1" colspan="1">−0.58 (0.99)</td>
                        <td align="left" rowspan="1" colspan="1">0.7628</td>
                        <td align="left" rowspan="1" colspan="1">8.1 (0.42) n=5</td>
                        <td align="left" rowspan="1" colspan="1">−0.36 (0.78)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fasting Plasma Glucose, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">119.1 (42.8)</td>
                        <td align="left" rowspan="1" colspan="1">−6.5 (24.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.0320</td>
                        <td align="left" colspan="2" rowspan="1">110.9 (29.9)</td>
                        <td align="left" rowspan="1" colspan="1">−2.2 (12.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.3155</td>
                        <td align="left" rowspan="1" colspan="1">120.3 (40.2)</td>
                        <td align="left" rowspan="1" colspan="1">−0.2 (14.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fasting Plasma FFA, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">0.6 (0.24)</td>
                        <td align="left" rowspan="1" colspan="1">−0.05 (0.18)</td>
                        <td align="left" rowspan="1" colspan="1">0.1245</td>
                        <td align="left" colspan="2" rowspan="1">0.5 (0.27)</td>
                        <td align="left" rowspan="1" colspan="1">−0.02 (0.28)</td>
                        <td align="left" rowspan="1" colspan="1">0.2437</td>
                        <td align="left" rowspan="1" colspan="1">0.5 (0.20)</td>
                        <td align="left" rowspan="1" colspan="1">0.05 (0.24)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fasting Plasma insulin, uU/L</td>
                        <td align="left" rowspan="1" colspan="1">20.5 (19.6)</td>
                        <td align="left" rowspan="1" colspan="1">−5.15 (22.00)</td>
                        <td align="left" rowspan="1" colspan="1">0.1967</td>
                        <td align="left" colspan="2" rowspan="1">26.1 (21.4)</td>
                        <td align="left" rowspan="1" colspan="1">−3.87 (10.53)</td>
                        <td align="left" rowspan="1" colspan="1">0.3295</td>
                        <td align="left" rowspan="1" colspan="1">21.2 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.06 (11.70)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">hsCRP, mg/L</td>
                        <td align="left" rowspan="1" colspan="1">2.7 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">1.3 (6.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.8524</td>
                        <td align="left" colspan="2" rowspan="1">3.0 (1.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.81 (5.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.9751</td>
                        <td align="left" rowspan="1" colspan="1">3.3 (3.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.07 (3.8)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Baseline Value</p>
                          <p>Mean (SD)</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>Change From Baseline</p>
                          <p>LS Mean (95% CI)</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HOMA‐IR</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6.1 (5.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">−2.04 (−2.9, −1.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.0056</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7.6 (7.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">−0.33 (−1.2, 0.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.9064</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6.6 (4.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">−0.39 (−1.3, 0.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Adipo‐IR</td>
                        <td align="char" char="(" rowspan="1" colspan="1">81.7 (65.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">−21.07 (−36.4, −5.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.0168</td>
                        <td align="char" char="(" rowspan="1" colspan="1">91.2 (70.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">−10.68 (−26.8, 5.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.1622</td>
                        <td align="char" char="(" rowspan="1" colspan="1">75.4 (62.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">3.66 (−12.5, 19.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah35420-ntgp-0004">
                    <fn id="jah35420-note-0007">
                      <p>Adipo‐IR indicates adipose tissue insulin resistance; FFA, free fatty acid; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HOMA‐IR, homeostatic model assessment for insulin resistance; hsCRP, high‐sensitivity C‐reactive protein; and LS, least squares.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <fig fig-type="Figure" xml:lang="en" id="jah35420-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <title>Change in HbA<sub>1c</sub>, glycemic, and insulin resistance parameters.</title>
                    <p><bold>A</bold>, Change in HbA<sub>1C</sub> (%) in placebo and epeleuton groups. <bold>B</bold>, Proportion of patients with HbA<sub>1c</sub> &gt;6.5% at baseline which is normal at week 16. <bold>C</bold>, Change in fasting plasma glucose in placebo and epeleuton groups. <bold>D</bold>, Change in plasma free fatty acids in placebo and epeleuton groups. <bold>E</bold>, Change in insulin in placebo and epeleuton groups. <bold>F</bold>, LS mean change in HOMA‐IR in placebo and epeleuton groups. <bold>G</bold>, LS mean change in Adipo‐IR in placebo and epeleuton groups. For (<bold>A</bold>,<bold> C</bold>,<bold> D</bold> and <bold>E</bold>) error bars denote standard error. For (<bold>F</bold> and <bold>G</bold>) error bars denote 95% CIs. Adipo‐IR indicates adipose tissue insulin resistance; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HOMA‐IR, homeostatic model assessment for insulin resistance; and LS, least squares. * denotes nonsignificant <italic>P</italic> values (&gt;0.05) compared with placebo.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e016334-g002"/>
                </fig>
              </sec>
              <sec id="jah35420-sec-0018">
                <title>Effects of Epeleuton on Triglycerides, Non–HDL‐C, VLDL‐C, and Other Lipid Parameters</title>
                <p>Epeleuton significantly decreased triglycerides and other atherogenic lipids from baseline to end‐of‐treatment (Figure <xref rid="jah35420-fig-0003" ref-type="fig">3</xref>, Table <xref rid="jah35420-tbl-0004" ref-type="table">4</xref> and Figure <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S1</xref>). In the mITT population, epeleuton 1 g/day reduced median triglyceride levels by 4.6% (<italic>P</italic>=0.016 versus placebo, <italic>P</italic>=0.94 versus baseline) and epeleuton 2 g/day reduced median triglyceride levels by 13.9% (<italic>P</italic>=0.0001 versus placebo, <italic>P</italic>=0.017 versus baseline). However, median triglyceride levels increased by 24.1% in the placebo group (<italic>P</italic>=0.008). Analysis of subgroups with elevated triglyceride levels at baseline indicated that in both epeleuton treatment groups, patients with higher baseline triglyceride levels exhibited greater improvements, whereas in the placebo group patients exhibited smaller changes from baseline (Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S4</xref>). In patients with triglycerides ≥150 mg/dL at baseline (n=52), treatment with epeleuton 1 and 2 g/day resulted in reductions of 20.3% (<italic>P</italic>=0.052 versus placebo) and 22.0% (<italic>P</italic>=0.011 versus placebo) compared with placebo, which exhibited a smaller change from baseline than in the mITT population (+13.9%). Greater reductions from baseline were observed for both epeleuton 1 g/day (−20.6%) and 2 g/day (−25.1%) in patients with triglycerides ≥200 mg/dL at baseline (n = 35), and no increase from baseline was observed for placebo‐treated patients (−5.0%).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35420-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <title>Median percentage change in lipid levels in patients receiving placebo, epeleuton 1 g/day or epeleuton 2 g/day (intention‐to‐treat population).</title>
                    <p><bold>A</bold>, Changes in lipid levels at week 16. <bold>B</bold>, Changes in triglycerides levels at week 16 in the mITT population and subgroups excluding outliers and with elevated triglycerides at baseline. <italic>P</italic> values are from the Wilcoxon rank‐sum test. Error bars denote 95% CIs. HDL‐C indicates high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; RLP‐C, remnant‐like particle cholesterol; and VLDL‐C, very‐low‐density lipoprotein cholesterol. *Denotes nonsignificant <italic>P</italic> values (&gt;0.05) compared with placebo.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-9-e016334-g003"/>
                </fig>
                <table-wrap id="jah35420-tbl-0004" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                  <label>Table 4</label>
                  <caption>
                    <p>Median Placebo‐Corrected Percentage Change in Lipid Levels in Patients Receiving Epeleuton 2 g/day or Epeleuton 1 g/day (Intention‐to‐Treat Population)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="center" colspan="6" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton</th>
                        <th align="center" rowspan="2" colspan="2" valign="top">Placebo (n=30)</th>
                        <th align="center" rowspan="2" colspan="2" valign="top">Between‐Group Differences</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 2 g/d (n=31)</th>
                        <th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Epeleuton 1 g/d (n=32)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">Baseline Value (mg/dL)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Percent Change From Baseline</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>vs Placebo</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Baseline Value (mg/dL)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Percent Change From Baseline</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p><italic>P</italic> Value</p>
                          <p>vs Placebo</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Baseline Value (mg/dL)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Percent Change From Baseline</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Epeleuton 2 g/d vs Placebo (%)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Epeleuton 1 g/d vs Placebo (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Triglycerides, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>242.0</p>
                          <p>(155.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−13.9</p>
                          <p>(48.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.017</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0001</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>146.0</p>
                          <p>(122.3)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−4.6</p>
                          <p>(54.2)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.94</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0163</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>150.0</p>
                          <p>(94.3)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>24.1</p>
                          <p>(47.9)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.008</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−40.2</p>
                          <p>(−60.1, −21.5)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−26.7</p>
                          <p>(−46.3, −7.1)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">VLDL‐C, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>48.0</p>
                          <p>(30.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−14.6</p>
                          <p>(52.9)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.06</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0003</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>28.5</p>
                          <p>(23.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0</p>
                          <p>(54.1)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.89</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0265</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>29.5</p>
                          <p>(18.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>24.1</p>
                          <p>(52.2)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.001</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−39.4</p>
                          <p>(−60.2, −18.6)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−25.7</p>
                          <p>(−45.1, −3.9)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non–HDL‐C, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>183.0</p>
                          <p>(95.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−7.0</p>
                          <p>(20.0)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.26</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0583</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>165.5</p>
                          <p>(42.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>4.2</p>
                          <p>(19.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.13</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.9117</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>165.0</p>
                          <p>(61.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>4.4</p>
                          <p>(23.1)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.14</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−8.1</p>
                          <p>(−17.5, 0.3)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.5</p>
                          <p>(−8.5, 8.8)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RLP‐C, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>45.0</p>
                          <p>(29.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−10.0</p>
                          <p>(48.4)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.25</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0031</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>28.5</p>
                          <p>(22.5)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0</p>
                          <p>(45.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.66</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0259</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>25.5</p>
                          <p>(15.3)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>21.2</p>
                          <p>(71.5)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.003</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−34.6</p>
                          <p>(−57.8, −11.9)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−23.1</p>
                          <p>(−45.2, −2.8)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>231.0</p>
                          <p>(89.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−4.8</p>
                          <p>(15.8)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.18</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0278</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>206.0</p>
                          <p>(42.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.1</p>
                          <p>(19.0)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.18</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.8382</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>213.5</p>
                          <p>(68.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>3.9</p>
                          <p>(16.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.06</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−8.0</p>
                          <p>(−14.9, −0.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−0.7</p>
                          <p>(−8.7, 6.6)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LDL‐C, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>133.0</p>
                          <p>(49.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−0.5</p>
                          <p>(24.4)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.92</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.8941</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>133.0</p>
                          <p>(59.5)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>5.5</p>
                          <p>(26.8)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.06</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.2366</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>138.5</p>
                          <p>(59.3)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−2.0</p>
                          <p>(24.4)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.76</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>−0.5</p>
                          <p>(−9.4, 8.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>5.8</p>
                          <p>(−5.1, 15.4)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL‐C, mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>41.0</p>
                          <p>(19.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0</p>
                          <p>(16.6)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.80</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.8590</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>43.5</p>
                          <p>(13.8)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>6.7</p>
                          <p>(16.7)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.0004</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.0686</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>42.0</p>
                          <p>(11.0)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0</p>
                          <p>(22.9)</p>
                          <p><xref ref-type="fn" rid="jah35420-note-0009">*</xref><italic>P</italic>=0.55</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.2</p>
                          <p>(−8.6, 8.4)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>6.7</p>
                          <p>(−0.3, 14.3)</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah35420-ntgp-0005">
                    <fn id="jah35420-note-0008">
                      <p>HDL‐C indicates high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; RLP‐C, remnant‐like particle cholesterol; and VLDL‐C, very‐low‐density lipoprotein cholesterol.</p>
                    </fn>
                    <fn id="jah35420-note-0009">
                      <label>a</label>
                      <p>Indicates <italic>P</italic> value of within‐group change from baseline. Baseline values and percent changes from baseline are presented as median (interquartile ranges). Median differences between treatment groups and 95% CIs were estimated with the Hodges‐Lehmann method. <italic>P</italic> values are from the Wilcoxon rank‐sum test.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Epeleuton did not affect LDL‐C levels relative to placebo at either dose. Similar to the dose‐dependent triglyceride‐lowering effect observed, epeleuton 2 g/day produced greater reductions of other lipid parameters than epeleuton 1 g/day. Epeleuton 2 g/day significantly reduced VLDL‐C (<italic>P</italic>=0.0003), RLP‐C (<italic>P</italic>=0.003) and total cholesterol (<italic>P</italic>=0.028) with no effect on HDL‐C. Epeleuton 2 g/day also reduced non–HDL‐C (<italic>P</italic>=0.058) (Table <xref rid="jah35420-tbl-0004" ref-type="table">4</xref>).</p>
              </sec>
              <sec id="jah35420-sec-0019">
                <title>Effects of Epeleuton on Glycemic Control and Insulin Sensitivity</title>
                <p>Epeleuton produced a dose‐dependent and significant decrease in HbA<sub>1c</sub> from baseline to end of treatment compared with placebo (Figure <xref rid="jah35420-fig-0002" ref-type="fig">2</xref>, Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref>, and Figures <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S2 and S3</xref>). Epeleuton 2 g/day significantly reduced mean HbA<sub>1C</sub> by 0.42% (<italic>P</italic>=0.026) compared with placebo (−0.08%). Epeleuton 1 g/day did not significantly reduce HbA<sub>1C</sub> compared with placebo. Analysis of subgroups by baseline HbA<sub>1c</sub> indicated that patients with higher HbA<sub>1c</sub> at baseline exhibited greater HbA<sub>1C</sub> improvements compared with the mITT population (Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref>). In patients with HbA<sub>1c</sub> &gt;6.5% at baseline (mean baseline HbA<sub>1c</sub>, 7.9%), treatment with epeleuton 2 g/day resulted in a significant mean HbA<sub>1c</sub> reduction of 1.13% (<italic>P</italic>=0.047; n=26) compared with placebo (−0.26%). Furthermore, among patients with HbA<sub>1c</sub> &gt;6.5% at baseline, a significantly greater proportion of patients in the epeleuton 2 g/day group (60.0%) than in the placebo group (12.5%) achieved an HbA<sub>1c</sub> &lt;6.5% at week 16 (<italic>P</italic>=0.034).</p>
                <p>Additionally, epeleuton produced consistent dose‐dependent reductions of multiple indicators of glycemic control and insulin sensitivity including fasting plasma glucose, insulin, and plasma free fatty acids, with greater reductions noted in the epeleuton 2 g/day group (Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="jah35420-fig-0002" ref-type="fig">2</xref>). Epeleuton 2 g/day significantly decreased fasting plasma glucose (mean change—epeleuton 2 g/day −6.5 mg/dL versus placebo −0.2 mg/dL; <italic>P</italic>=0.032). Epeleuton did not affect blood pressure or body weight (Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S5</xref>).</p>
              </sec>
              <sec id="jah35420-sec-0020">
                <title>Effects of Epeleuton on Markers of Cardiovascular Risk and Inflammation</title>
                <p>HsCRP did not change significantly compared with placebo in either of the epeleuton treatment groups (Table <xref rid="jah35420-tbl-0003" ref-type="table">3</xref>). However, epeleuton 2 g/day significantly decreased multiple circulating inflammatory markers including cellular adhesion molecules, chemokines, tumor necrosis factor receptor superfamily members, and other biomarkers of cardiovascular risk and diabetes mellitus (Table <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S6</xref> and Figures <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S4 through S8</xref>). Epeleuton 1 g/day and placebo did not produce significant decreases of markers of cardiovascular risk and inflammation (Tables <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S7 and S8</xref>).</p>
              </sec>
              <sec id="jah35420-sec-0021">
                <title>Plasma 15(S)‐HEPE Concentrations</title>
                <p>All plasma unesterified 15(S)‐HEPE concentrations were below quantifiable limits for predose samples in all treatment groups as well as for most postdose samples for the placebo group. Predose plasma total 15(S)‐HEPE concentrations were detectable, were similar for placebo, epeleuton 1 g/day, and epeleuton 2 g/day.</p>
                <p>Plasma 15(S)‐HEPE concentrations were at pharmacokinetic steady state by 4 weeks and were maintained throughout the 16‐week treatment period. Mean plasma unesterified 15(S)‐HEPE concentrations across trial weeks 2 through 16 were 43.5 and 62.0 ng/mL for epeleuton 1 and 2 g/day, respectively. Mean plasma total 15(S)‐HEPE concentrations across trial weeks 2 through 16 were 355 and 952 ng/mL for epeleuton and 2 g/day, respectively. Concentrations of 15(S)‐HEPE generally increased in a dose‐dependent manner. Concentration versus time profiles for plasma total and unesterified 15(S)‐HEPE in each of the treatment groups are presented in Figures <xref rid="jah35420-sup-0001" ref-type="supplementary-material">S9 and S10</xref>.</p>
              </sec>
              <sec id="jah35420-sec-0022">
                <title>Safety</title>
                <p>Treatment‐emergent adverse events AEs were reported in 15 (45.5%) patients in the epeleuton 2 g/day group, 20 (62.5%) patients in the epeleuton 1 g/day group and 17 (54.8%) patients in the placebo group. Most treatment‐emergent AEs were mild‐to‐moderate in severity and considered unrelated to study drug. The most common treatment‐emergent AEs were gastrointestinal disorders which were mild‐to‐moderate in intensity and occurred in 6 (18.2%) patients in the epeleuton 2 g/day group, 9 (28.1%) patients in the epeleuton 1 g/day group and 7 (22.6%) patients in the placebo group. One patient in the placebo group (3.2%) discontinued treatment because of a treatment‐emergent AE. No patients in the epeleuton groups discontinued treatment due to an adverse event. In total, 2 non–study drug–related serious AEs were reported during the trial, a pilonidal cyst in a patient in the placebo group and schizophrenia in a patient in the epeleuton 2 g/day group. No serious AEs were considered related to the study drug. No clinically meaningful adverse changes in laboratory parameters, electrocardiographic parameters, vital signs, or physical examinations were noted.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah35420-sec-0023">
              <title>Discussion</title>
              <p>In this phase 2a trial, the primary end points of changes in serum ALT and liver stiffness were not met at either dose of epeleuton at 16 weeks. Although numerical decreases were observed in all treatment groups, changes from baseline were significant only in the placebo group that had notably higher median ALT and liver stiffness levels at baseline compared with the epeleuton treatment groups, possibly indicating a regression to the mean effect.</p>
              <p>Epeleuton 2 g/day significantly decreased hepatic fat from baseline, although the between‐group comparison between epeleuton 2 g/day and placebo was not significant at week 16. These results are consistent with other short‐duration n‐3 fatty acid studies in patients with NAFLD.<xref rid="jah35420-bib-0031" ref-type="ref"><sup>31</sup></xref>, <xref rid="jah35420-bib-0032" ref-type="ref"><sup>32</sup></xref> In a phase 2 trial conducted to investigate the effect of dapaglifozin monotherapy, n‐3 carboxylic acid (EPA and docosahexanoic acid) monotherapy and combination treatment with dapaglifozin and n‐3 carboxylic acids on hepatic fat in patients with NAFLD and type 2 diabetes mellitus, both monotherapy groups had significant decreases in hepatic fat from baseline after 12 weeks of treatment, but no significant change occurred in the placebo group. However, only the combination treatment reduced hepatic fat significantly compared with placebo. Notably, n‐3 carboxylic acids did not significantly decrease the levels of hepatocellular injury biomarkers including serum ALT despite the effects on hepatic fat.<xref rid="jah35420-bib-0031" ref-type="ref"><sup>31</sup></xref> Both the significant decrease of hepatic fat from baseline and the lack of effect on ALT with n‐3 carboxylic acids mirror the results of the present trial with epeleuton, though, given baseline differences, further studies are needed to validate such findings.</p>
              <p>We hypothesized that epeleuton would have beneficial effects in patients with NAFLD because of improvements in liver histology, hepatic fat content, and inflammation observed in preclinical studies and the reported effects of n‐3 fatty acids on fatty acid oxidation and hepatic fat.<xref rid="jah35420-bib-0025" ref-type="ref"><sup>25</sup></xref> Although the primary end points were not met in the present trial, changes in hepatic fat indicate a potential utility for epeleuton in the treatment of NAFLD that requires further investigation. Future studies may need to consider longer treatment durations to establish the full effect of epeleuton on hepatic steatosis and combinatorial approaches with complementary therapies to address the multiplicity of pathways responsible for the development of fatty liver injury.</p>
              <p>Furthermore, epeleuton decreased triglycerides, VLDL‐C, RLP‐C, total cholesterol, and non–HDL‐C in a dose‐dependent manner, although increases were seen in the placebo group. Additionally, analyses of subgroups with elevated triglycerides at baseline, ≥150 mg/dL, and ≥200 mg/dL demonstrated greater reductions at both doses of epeleuton, suggesting that in a prospectively selected hypertriglyceridemic population, further reductions may be achieved.</p>
              <p>The observed reductions in triglycerides with an EPA derivative, while post hoc and hypothesis generating, are particularly relevant after the REDUCE‐IT trial that demonstrated treatment of patients with hypertriglyceridemia on optimized statins with icosapent ethyl resulted in significant reductions in major adverse cardiovascular outcomes. As a result, the REDUCE‐IT results have established a new paradigm for residual cardiovascular risk reduction.<xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0033" ref-type="ref"><sup>33</sup></xref> Furthermore, despite the lower daily dose of epeleuton, the reductions of triglycerides observed in the present trial are comparable to those seen in REDUCE‐IT and ANCHOR (Effect of AMR101 [Ethyl Icosapentate] on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥200 and &lt;500 mg/dL), a phase III trial of icosapent ethyl in patients with high triglyceride levels.<xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0034" ref-type="ref"><sup>34</sup></xref> However, it should be acknowledged that differences in trial populations limit the scope of such comparisons.</p>
              <p>Notably, the therapeutic effects of epeleuton on multiple lipids were observed without an increase in LDL‐C. This is consistent with results from studies with other EPA‐axis n‐3 fatty acid treatments.<xref rid="jah35420-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35420-bib-0011" ref-type="ref"><sup>11</sup></xref>, <xref rid="jah35420-bib-0034" ref-type="ref"><sup>34</sup></xref> Definitive differences in cardiovascular outcomes between EPA axis treatments and combination EPA/docosahexaenoic acid treatments will be clarified following the results of the STRENGTH (Statin Residual Risk Reduction With EpaNova in High Cardiovascular Risk Patients With Hypertriglyceridemia) trial, an event‐driven trial of n‐3 carboxylic acids, in statin‐treated patients with high triglyceride and low HDL‐C levels.<xref rid="jah35420-bib-0035" ref-type="ref"><sup>35</sup></xref> Notably, the STRENGTH trial has been discontinued following the recommendation of an independent data monitoring committee because of a low likelihood of demonstrating a benefit to patients.<xref rid="jah35420-bib-0036" ref-type="ref"><sup>36</sup></xref>
</p>
              <p>Although other studies with n‐3 fatty acids including icosapent ethyl and other EPA preparations have demonstrated a triglyceride‐lowering effect, this has not been associated with an improvement of glycemic control or insulin resistance.<xref rid="jah35420-bib-0034" ref-type="ref"><sup>34</sup></xref>, <xref rid="jah35420-bib-0037" ref-type="ref"><sup>37</sup></xref> Instead, it had been speculated that non‐EPA n‐3 fatty acids may increase HbA<sub>1c</sub> levels and predispose to the development of diabetes mellitus.<xref rid="jah35420-bib-0038" ref-type="ref"><sup>38</sup></xref> In the present trial, epeleuton 2 g/day significantly decreased, rather than increased, HbA<sub>1c</sub> at week 16 despite a relatively low mean baseline HbA<sub>1c</sub> (6.3%). Analysis of subgroups by baseline HbA<sub>1c</sub> levels indicated that patients with higher HbA<sub>1c</sub> at baseline exhibited greater improvements. In patients with HbA<sub>1c</sub> &gt;6.5% at baseline, epeleuton significantly decreased HbA<sub>1c</sub> by 1.13%. The HbA<sub>1c</sub>‐lowering effects seen in this trial, while post hoc and hypothesis generating, indicate epeleuton's potential as a novel antihyperglycemic agent for patients with type 2 diabetes mellitus. Importantly, the results in the subgroup analyses, although in a small sample, are comparable to those seen after treatment with most established antihyperglycemics for longer durations of 24 weeks or more.<xref rid="jah35420-bib-0039" ref-type="ref"><sup>39</sup></xref>, <xref rid="jah35420-bib-0040" ref-type="ref"><sup>40</sup></xref>
</p>
              <p>Epeleuton's effects on hyperglycemia and insulin resistance are also evident in the broadly consistent decreases of multiple parameters including fasting plasma glucose, insulin, and free fatty acids. In this trial, treatment with epeleuton 2 g/day produced significant decreases of HOMA‐IR, which quantifies insulin resistance and beta cell function and correlates with estimates using euglycemic clamp methods.<xref rid="jah35420-bib-0027" ref-type="ref"><sup>27</sup></xref>
</p>
              <p>One of the potential explanations for increased risk in patients with high triglycerides is the presence of a proinflammatory state.<xref rid="jah35420-bib-0041" ref-type="ref"><sup>41</sup></xref> In fact, it has been speculated that the effects of icosapent ethyl on rates of ischemic events in the REDUCE‐IT trial are not fully explained by its triglyceride‐lowering effect.<xref rid="jah35420-bib-0042" ref-type="ref"><sup>42</sup></xref> It is postulated that an anti‐inflammatory effect may have contributed to the magnitude of reduction seen in REDUCE‐IT. In the present analysis, epeleuton 2 g/day did not decrease hsCRP but significantly decreased the circulating levels of an array of chemokines, adhesion molecules, tumor necrosis factor receptor superfamily members, and other markers of endothelial dysfunction, cardiovascular, and diabetes mellitus risk. Notably, in phase 3 studies of icosapent ethyl, reductions of hsCRP compared with baseline levels were observed only at the higher 4 g/day dose and not at the 2 g/day dose, which may suggest that similarly a higher dose of epeleuton is required to decrease hsCRP.<xref rid="jah35420-bib-0034" ref-type="ref"><sup>34</sup></xref>, <xref rid="jah35420-bib-0043" ref-type="ref"><sup>43</sup></xref> The positive data at the 2 g/day dose and the lack of effect of the lower dose of epeleuton on most inflammatory markers provide mechanistic indications that epeleuton may exert a meaningful systemic and/or tissue‐level anti‐inflammatory effect when administered above a certain dose threshold. These findings also suggest there is merit in examining a dose of 4 g/day in the future.</p>
              <p>In summary, the present work builds on the accumulating evidence that multiple strategies may delay the progression of atherosclerosis and reduce the incidence of ischemic events. Treatment of hypertriglyceridemia, hyperglycemia, and inflammation have been individually shown to effectively reduce cardiovascular risk and the rate of ischemic events. Epeleuton is a synthetic EPA‐derived second‐generation n‐3 fatty acid with a therapeutic profile distinct from other n‐3 fatty acids. The results of this trial, while post hoc and exploratory, have identified epeleuton's unique potential to address synergistically multiple axes of cardiovascular risk and several aspects of the metabolic syndrome.</p>
              <sec id="jah35420-sec-0024">
                <title>Limitations</title>
                <p>The present results are partly based on post hoc analyses, which include subgroups. Although comparisons were made between randomized groups, minimizing the risk of residual confounding, it cannot be fully excluded. Of note, LDL cholesterol levels were not optimized at baseline, and most patients were not on a statin. Additionally, baseline ALT and liver stiffness levels were higher in the placebo group, and baseline triglyceride levels were higher in the epeleuton 2 g/day group. The reported positive post hoc results indicate meaningful therapeutic potential, but they are hypothesis generating and must be reproduced prospectively in patients with hypertriglyceridemia and type 2 diabetes mellitus.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah35420-sec-0025">
              <title>Conclusions</title>
              <p>Epeleuton was well tolerated, with a safety profile not different from placebo, and although the primary end‐points of serum ALT and liver stiffness were not met, its administration was associated with significant dose‐dependent decreases of triglycerides, total cholesterol, and multiple atherogenic lipids without raising LDL‐C. Additionally, epeleuton meaningfully decreased HbA1c and fasting plasma glucose, and improved insulin resistance and systemic levels of inflammation and endothelial dysfunction markers. These data suggest that epeleuton may have important therapeutic potential for cardiovascular risk reduction by simultaneously targeting hypertriglyceridemia, hyperglycemia, and inflammation. Further studies will be necessary to confirm these hypothesis‐generating findings and to investigate the full therapeutic effects of epeleuton for the treatment of NAFLD, hyperglycemia and diabetes mellitus, dyslipidemia, and prevention of ischemic events.</p>
            </sec>
            <sec id="jah35420-sec-0027">
              <title>Sources of Funding</title>
              <p>This work was supported by Afimmune. Afimmune was involved in the design and conduct of the trial, collection, analysis, and interpretation of data; and preparation of this manuscript. Dr Newsome was supported by the National Institute of Health Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah35420-sec-0028">
              <title>Disclosures</title>
              <p>Dr Climax is the CEO and a shareholder of Afimmune and DS Biopharma. Dr Newsome has received grants, consultancy, and nonfinancial support from Novo Nordisk; consultancy from Shire; grants and consultancy from Boehringer Ingelheim; consultancy from Intercept Pharmaceuticals; consultancy from Afimmune; speaker fees from Norgine; consultancy from Gilead Sciences; and consultancy from Pfizer. Drs Hamza, Weissbach, and Coughlan are employees of Afimmune and DS Biopharma. Dr Sattar has consulted for, or received speaker fees from, Afimmune, Amgen, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi, and Janssen and has received research grant support from Boehringer Ingelheim. Dr McGuire has received honoraria for clinical trial leadership from AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck &amp; Co, Pfizer, Novo Nordisk, Lexicon, Eisai Inc, GlaxoSmithKline, and Esperion and honoraria for consultancy from AstraZeneca, Sanofi Aventis, Eli Lilly and Company, Boehringer Ingelheim, Merck &amp; Co, Pfizer, Novo Nordisk, Metavant, Applied Therapeutics, and Afimmune. Dr Bhatt discloses the following relationships—Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice‐Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE‐DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS‐II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <italic>Harvard Heart Letter</italic>), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE [A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease] trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, <italic>Journal of Invasive Cardiology</italic>), <italic>Journal of the American College of Cardiology</italic> (Guest Editor; Associate Editor), K2P (Co‐Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co‐leader, funded by Bayer), Slack Publications (Chief Medical Editor, <italic>Cardiology Today's Intervention</italic>), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: <italic>Clinical Cardiology</italic> (Deputy Editor), NCDR‐ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, <italic>Cardiovascular Intervention: A Companion to Braunwald's Heart Disease</italic>); Site Co‐Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah35420-sup-0001">
                <caption>
                  <p>
                    <bold>Tables S1–S8</bold>
                  </p>
                  <p>
                    <bold>Figures S1–S10</bold>
                  </p>
                </caption>
                <media xlink:href="JAH3-9-e016334-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah35420-sec-0026">
              <title>Acknowledgments</title>
              <p>The authors thank all patients and investigators who participated in the trial. The authors thank Prof Naga P. Chalasani, Prof Arun J. Sanyal, and Prof Scott L. Friedman for their valuable contributions to the clinical development of epeleuton.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah35420-bibl-0001">
              <title>References</title>
              <ref id="jah35420-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0001"><string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Forrest</surname><given-names>E</given-names></string-name>, <string-name><surname>Preiss</surname><given-names>D</given-names></string-name>. <article-title>Non‐alcoholic fatty liver disease</article-title>. <source xml:lang="en">BMJ</source>. <year>2014</year>;<fpage>g4596</fpage>.<pub-id pub-id-type="pmid">25239614</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0002"><string-name><surname>Herrington</surname><given-names>W</given-names></string-name>, <string-name><surname>Lacey</surname><given-names>B</given-names></string-name>, <string-name><surname>Sherliker</surname><given-names>P</given-names></string-name>, <string-name><surname>Armitage</surname><given-names>J</given-names></string-name>, <string-name><surname>Lewington</surname><given-names>S</given-names></string-name>. <article-title>Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease</article-title>. <source xml:lang="en">Circ Res</source>. <year>2016</year>;<fpage>535</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">26892956</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0003"><collab collab-type="authors">Anon</collab>
. <article-title>Global, regional, and national age–sex specific all‐cause and cause‐specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>. <source xml:lang="en">Lancet</source>. <year>2015</year>;<fpage>117</fpage>–<lpage>171</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0004"><string-name><surname>Zelniker</surname><given-names>TA</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Raz</surname><given-names>I</given-names></string-name>, <string-name><surname>Im</surname><given-names>K</given-names></string-name>, <string-name><surname>Goodrich</surname><given-names>EL</given-names></string-name>, <string-name><surname>Furtado</surname><given-names>RHM</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>MP</given-names></string-name>, <string-name><surname>Mosenzon</surname><given-names>O</given-names></string-name>, <string-name><surname>Kato</surname><given-names>ET</given-names></string-name>, <string-name><surname>Cahn</surname><given-names>A</given-names></string-name>, et al. <article-title>Comparison of the effects of glucagon‐like peptide receptor agonists and sodium‐glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus</article-title>. <source xml:lang="en">Circulation</source>. <year>2019</year>;<fpage>2022</fpage>–<lpage>2031</lpage>.<pub-id pub-id-type="pmid">30786725</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0005"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>TA</given-names></string-name>, <string-name><surname>Ketchum</surname><given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>RT</given-names></string-name>, <string-name><surname>Juliano</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Granowitz</surname><given-names>C</given-names></string-name>, et al. <article-title>Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<fpage>11</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">30415628</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0006"><string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Everett</surname><given-names>BM</given-names></string-name>, <string-name><surname>Thuren</surname><given-names>T</given-names></string-name>, <string-name><surname>MacFadyen</surname><given-names>JG</given-names></string-name>, <string-name><surname>Chang</surname><given-names>WH</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>C</given-names></string-name>, <string-name><surname>Fonseca</surname><given-names>F</given-names></string-name>, <string-name><surname>Nicolau</surname><given-names>J</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, et al. <article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>;<fpage>1119</fpage>–<lpage>1131</lpage>.<pub-id pub-id-type="pmid">28845751</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0007"><string-name><surname>Verma</surname><given-names>S</given-names></string-name>, <string-name><surname>Leiter</surname><given-names>LA</given-names></string-name>, <string-name><surname>Mazer</surname><given-names>CD</given-names></string-name>, <string-name><surname>Bain</surname><given-names>SC</given-names></string-name>, <string-name><surname>Buse</surname><given-names>J</given-names></string-name>, <string-name><surname>Marso</surname><given-names>S</given-names></string-name>, <string-name><surname>Nauck</surname><given-names>M</given-names></string-name>, <string-name><surname>Zinman</surname><given-names>B</given-names></string-name>, <string-name><surname>Bosch‐Traberg</surname><given-names>H</given-names></string-name>, <string-name><surname>Rasmussen</surname><given-names>S</given-names></string-name>, et al. <article-title>Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low‐density lipoprotein cholesterol levels and statin use: results from the LEADER trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2018</year>;<fpage>1605</fpage>–<lpage>1607</lpage>.<pub-id pub-id-type="pmid">30354517</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0008"><string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <string-name><surname>Seshasai</surname><given-names>SRK</given-names></string-name>, <string-name><surname>Wijesuriya</surname><given-names>S</given-names></string-name>, <string-name><surname>Sivakumaran</surname><given-names>R</given-names></string-name>, <string-name><surname>Nethercott</surname><given-names>S</given-names></string-name>, <string-name><surname>Preiss</surname><given-names>D</given-names></string-name>, <string-name><surname>Erqou</surname><given-names>S</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>. <article-title>Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta‐analysis of randomised controlled trials</article-title>. <source xml:lang="en">Lancet</source>. <year>2009</year>;<fpage>1765</fpage>–<lpage>1772</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0009"><string-name><surname>Ross</surname><given-names>S</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Eikelboom</surname><given-names>J</given-names></string-name>, <string-name><surname>Anand</surname><given-names>SS</given-names></string-name>, <string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Paré</surname><given-names>G</given-names></string-name>. <article-title>Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2015</year>;<fpage>1454</fpage>–<lpage>1462</lpage>.<pub-id pub-id-type="pmid">25825043</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0010"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>. <article-title>Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2015</year>;<fpage>1424</fpage>–<lpage>1427</lpage>.<pub-id pub-id-type="pmid">25827603</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0011"><string-name><surname>Yokoyama</surname><given-names>M</given-names></string-name>, <string-name><surname>Origasa</surname><given-names>H</given-names></string-name>, <string-name><surname>Matsuzaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Matsuzawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Saito</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ishikawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Oikawa</surname><given-names>S</given-names></string-name>, <string-name><surname>Sasaki</surname><given-names>J</given-names></string-name>, <string-name><surname>Hishida</surname><given-names>H</given-names></string-name>, <string-name><surname>Itakura</surname><given-names>H</given-names></string-name>, et al. <article-title>Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis</article-title>. <source xml:lang="en">Lancet</source>. <year>2007</year>;<fpage>1090</fpage>–<lpage>1098</lpage>.<pub-id pub-id-type="pmid">17398308</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0012"><string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <string-name><surname>Ginsberg</surname><given-names>HN</given-names></string-name>, <string-name><surname>Chapman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Packard</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Laufs</surname><given-names>U</given-names></string-name>, <string-name><surname>Oliver‐Williams</surname><given-names>C</given-names></string-name>, <string-name><surname>Wood</surname><given-names>AM</given-names></string-name>, <string-name><surname>Butterworth</surname><given-names>AS</given-names></string-name>, et al. <article-title>Association of triglyceride‐lowering LPL variants and LDL‐C–lowering LDLR variants with risk of coronary heart disease</article-title>. <source xml:lang="en">JAMA</source>. <year>2019</year>;<fpage>364</fpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0013"><string-name><surname>Nichols</surname><given-names>GA</given-names></string-name>, <string-name><surname>Philip</surname><given-names>S</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>K</given-names></string-name>, <string-name><surname>Granowitz</surname><given-names>CB</given-names></string-name>, <string-name><surname>Fazio</surname><given-names>S</given-names></string-name>. <article-title>Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2019</year>;<fpage>366</fpage>–<lpage>371</lpage>.<pub-id pub-id-type="pmid">30225881</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0014"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>TA</given-names></string-name>, <string-name><surname>Ketchum</surname><given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>RT</given-names></string-name>, <string-name><surname>Juliano</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Granowitz</surname><given-names>C</given-names></string-name>, et al. <article-title>Effects of icosapent ethyl on total ischemic events</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2019</year>;<fpage>2791</fpage>–<lpage>2802</lpage>.<pub-id pub-id-type="pmid">30898607</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0015"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>TA</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Ketchum</surname><given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>RT</given-names></string-name>, <string-name><surname>Juliano</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Granowitz</surname><given-names>C</given-names></string-name>, et al. <article-title>REDUCE‐IT USA: results from the 3,146 patients randomized in the United States</article-title>. <source xml:lang="en">Circulation</source>. <year>2020</year>;<fpage>367</fpage>–<lpage>375</lpage>.<pub-id pub-id-type="pmid">31707829</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0016"><string-name><surname>Ganda</surname><given-names>OP</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Mason</surname><given-names>RP</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Boden</surname><given-names>WE</given-names></string-name>. <article-title>Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2018</year>;<fpage>330</fpage>–<lpage>343</lpage>.<pub-id pub-id-type="pmid">29935936</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0017"><string-name><surname>Patel</surname><given-names>PN</given-names></string-name>, <string-name><surname>Patel</surname><given-names>SM</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>. <article-title>Cardiovascular risk reduction with icosapent ethyl</article-title>. <source xml:lang="en">Curr Opin Cardiol</source>. <year>2019</year>;<fpage>721</fpage>–<lpage>727</lpage>.<pub-id pub-id-type="pmid">31464773</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0018"><string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Raz</surname><given-names>I</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>MP</given-names></string-name>, <string-name><surname>Mosenzon</surname><given-names>O</given-names></string-name>, <string-name><surname>Kato</surname><given-names>ET</given-names></string-name>, <string-name><surname>Cahn</surname><given-names>A</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>MG</given-names></string-name>, <string-name><surname>Zelniker</surname><given-names>TA</given-names></string-name>, <string-name><surname>Kuder</surname><given-names>JF</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>SA</given-names></string-name>, et al. <article-title>Dapagliflozin and cardiovascular outcomes in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<fpage>347</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">30415602</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0019"><string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <string-name><surname>de Zeeuw</surname><given-names>D</given-names></string-name>, <string-name><surname>Fulcher</surname><given-names>G</given-names></string-name>, <string-name><surname>Erondu</surname><given-names>N</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>W</given-names></string-name>, <string-name><surname>Law</surname><given-names>G</given-names></string-name>, <string-name><surname>Desai</surname><given-names>M</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>DR</given-names></string-name>. <article-title>Canagliflozin and cardiovascular and renal events in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>;<fpage>644</fpage>–<lpage>657</lpage>.<pub-id pub-id-type="pmid">28605608</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0020"><string-name><surname>Marso</surname><given-names>SP</given-names></string-name>, <string-name><surname>Daniels</surname><given-names>GH</given-names></string-name>, <string-name><surname>Brown‐Frandsen</surname><given-names>K</given-names></string-name>, <string-name><surname>Kristensen</surname><given-names>P</given-names></string-name>, <string-name><surname>Mann</surname><given-names>JFE</given-names></string-name>, <string-name><surname>Nauck</surname><given-names>MA</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>S</given-names></string-name>, <string-name><surname>Poulter</surname><given-names>NR</given-names></string-name>, <string-name><surname>Ravn</surname><given-names>LS</given-names></string-name>, et al. <article-title>Liraglutide and cardiovascular outcomes in type 2 diabetes</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<fpage>311</fpage>–<lpage>322</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0021"><string-name><surname>Zelniker</surname><given-names>TA</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Raz</surname><given-names>I</given-names></string-name>, <string-name><surname>Im</surname><given-names>K</given-names></string-name>, <string-name><surname>Goodrich</surname><given-names>EL</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>MP</given-names></string-name>, <string-name><surname>Mosenzon</surname><given-names>O</given-names></string-name>, <string-name><surname>Kato</surname><given-names>ET</given-names></string-name>, <string-name><surname>Cahn</surname><given-names>A</given-names></string-name>, <string-name><surname>Furtado</surname><given-names>RHM</given-names></string-name>, et al. <article-title>SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials</article-title>. <source xml:lang="en">Lancet</source>. <year>2019</year>;<fpage>31</fpage>–<lpage>39</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0022"><string-name><surname>Scirica</surname><given-names>BM</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>J</given-names></string-name>, <string-name><surname>Hirshberg</surname><given-names>B</given-names></string-name>, <string-name><surname>Ohman</surname><given-names>P</given-names></string-name>, <string-name><surname>Frederich</surname><given-names>R</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>EB</given-names></string-name>, et al. <article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2013</year>;<fpage>1317</fpage>–<lpage>1326</lpage>.<pub-id pub-id-type="pmid">23992601</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0023"><string-name><surname>Vang</surname><given-names>K</given-names></string-name>, <string-name><surname>Ziboh</surname><given-names>VA</given-names></string-name>. <article-title>15‐lipoxygenase metabolites of gamma‐linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids</article-title>. <source xml:lang="en">Prostaglandins Leukot Essent Fatty Acids</source>. <year>2005</year>;<fpage>363</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">15850718</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0024"><string-name><surname>Schuchardt</surname><given-names>JP</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>I</given-names></string-name>, <string-name><surname>Willenberg</surname><given-names>I</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Hammock</surname><given-names>BD</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>A</given-names></string-name>, <string-name><surname>Schebb</surname><given-names>NH</given-names></string-name>. <article-title>Increase of EPA‐derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long‐chain omega‐3 PUFA</article-title>. <source xml:lang="en">Prostaglandins Other Lipid Mediat</source>. <year>2014</year>;<fpage>23</fpage>–<lpage>31</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0025"><string-name><surname>Couet</surname><given-names>C</given-names></string-name>, <string-name><surname>Delarue</surname><given-names>J</given-names></string-name>, <string-name><surname>Ritz</surname><given-names>P</given-names></string-name>, <string-name><surname>Antoine</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lamisse</surname><given-names>F</given-names></string-name>. <article-title>Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults</article-title>. <source xml:lang="en">Int J Obes Relat Metab Disord</source>. <year>1997</year>;<fpage>637</fpage>–<lpage>643</lpage>.<pub-id pub-id-type="pmid">15481762</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0026"><string-name><surname>Sasso</surname><given-names>M</given-names></string-name>, <string-name><surname>Beaugrand</surname><given-names>M</given-names></string-name>, <string-name><surname>de Ledinghen</surname><given-names>V</given-names></string-name>, <string-name><surname>Douvin</surname><given-names>C</given-names></string-name>, <string-name><surname>Marcellin</surname><given-names>P</given-names></string-name>, <string-name><surname>Poupon</surname><given-names>R</given-names></string-name>, <string-name><surname>Sandrin</surname><given-names>L</given-names></string-name>, <string-name><surname>Miette</surname><given-names>V</given-names></string-name>. <article-title>Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes</article-title>. <source xml:lang="en">Ultrasound Med Biol</source>. <year>2010</year>;<fpage>1825</fpage>–<lpage>1835</lpage>.<pub-id pub-id-type="pmid">20870345</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0027"><string-name><surname>Matthews</surname><given-names>DR</given-names></string-name>, <string-name><surname>Hosker</surname><given-names>JP</given-names></string-name>, <string-name><surname>Rudenski</surname><given-names>AS</given-names></string-name>, <string-name><surname>Naylor</surname><given-names>BA</given-names></string-name>, <string-name><surname>Treacher</surname><given-names>DF</given-names></string-name>, <string-name><surname>Turner</surname><given-names>RC</given-names></string-name>. <article-title>Homeostasis model assessment: insulin resistance and β‐cell function from fasting plasma glucose and insulin concentrations in man</article-title>. <source xml:lang="en">Diabetologia</source>. <year>1985</year>;<fpage>412</fpage>–<lpage>419</lpage>.<pub-id pub-id-type="pmid">3899825</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0028"><string-name><surname>Gastaldelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Gaggini</surname><given-names>M</given-names></string-name>, <string-name><surname>DeFronzo</surname><given-names>RA</given-names></string-name>. <article-title>Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio Metabolism Study</article-title>. <source xml:lang="en">Diabetes</source>. <year>2017</year>;<fpage>815</fpage>–<lpage>822</lpage>.<pub-id pub-id-type="pmid">28052966</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0029"><string-name><surname>Assarsson</surname><given-names>E</given-names></string-name>, <string-name><surname>Lundberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Holmquist</surname><given-names>G</given-names></string-name>, <string-name><surname>Björkesten</surname><given-names>J</given-names></string-name>, <string-name><surname>Thorsen</surname><given-names>SB</given-names></string-name>, <string-name><surname>Ekman</surname><given-names>D</given-names></string-name>, <string-name><surname>Eriksson</surname><given-names>A</given-names></string-name>, <string-name><surname>Dickens</surname><given-names>ER</given-names></string-name>, <string-name><surname>Ohlsson</surname><given-names>S</given-names></string-name>, <string-name><surname>Edfeldt</surname><given-names>G</given-names></string-name>, et al. <article-title>Homogenous 96‐plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability</article-title>. <source xml:lang="en">PLoS One</source>. <year>2014</year>;<volume>9</volume>:<elocation-id>e95192</elocation-id>.<pub-id pub-id-type="pmid">24755770</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0030"><string-name><surname>Benjamini</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y</given-names></string-name>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source xml:lang="en">J R Statist Soc B</source>. <year>1995</year>;<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0031"><string-name><surname>Eriksson</surname><given-names>JW</given-names></string-name>, <string-name><surname>Lundkvist</surname><given-names>P</given-names></string-name>, <string-name><surname>Jansson</surname><given-names>P‐A</given-names></string-name>, <string-name><surname>Johansson</surname><given-names>L</given-names></string-name>, <string-name><surname>Kvarnström</surname><given-names>M</given-names></string-name>, <string-name><surname>Moris</surname><given-names>L</given-names></string-name>, <string-name><surname>Miliotis</surname><given-names>T</given-names></string-name>, <string-name><surname>Forsberg</surname><given-names>G‐B</given-names></string-name>, <string-name><surname>Risérus</surname><given-names>U</given-names></string-name>, <string-name><surname>Lind</surname><given-names>L</given-names></string-name>, et al. <article-title>Effects of dapagliflozin and n‐3 carboxylic acids on non‐alcoholic fatty liver disease in people with type 2 diabetes: a double‐blind randomised placebo‐controlled study</article-title>. <source xml:lang="en">Diabetologia</source>. <year>2018</year>;<fpage>1923</fpage>–<lpage>1934</lpage>.<pub-id pub-id-type="pmid">29971527</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0032"><string-name><surname>Spooner</surname><given-names>MH</given-names></string-name>, <string-name><surname>Jump</surname><given-names>DB</given-names></string-name>. <article-title>Omega‐3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?</article-title><source xml:lang="en">Curr Opin Clin Nutr Metab Care</source>. <year>2019</year>;<fpage>103</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">30601174</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0033"><string-name><surname>Boden</surname><given-names>WE</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Toth</surname><given-names>PP</given-names></string-name>, <string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <string-name><surname>Chapman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Lüscher</surname><given-names>TF</given-names></string-name>. <article-title>Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE‐IT trial: why these results usher in a new era in dyslipidaemia therapeutics</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2020</year>;<fpage>2304</fpage>–<lpage>2312</lpage>.<pub-id pub-id-type="pmid">31872245</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0034"><string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Bays</surname><given-names>HE</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Stein</surname><given-names>E</given-names></string-name>, <string-name><surname>Isaacsohn</surname><given-names>JL</given-names></string-name>, <string-name><surname>Braeckman</surname><given-names>RA</given-names></string-name>, <string-name><surname>Soni</surname><given-names>PN</given-names></string-name>. <article-title>Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin‐treated patients with persistent high triglycerides (from the ANCHOR study)</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2012</year>;<fpage>984</fpage>–<lpage>992</lpage>.<pub-id pub-id-type="pmid">22819432</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0035"><string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lincoff</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bash</surname><given-names>D</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>MH</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, et al. <article-title>Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial</article-title>. <source xml:lang="en">Clin Cardiol</source>. <year>2018</year>;<fpage>1281</fpage>–<lpage>1288</lpage>.<pub-id pub-id-type="pmid">30125052</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="miscellaneous" id="jah35420-cit-0036"><article-title>Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia. (AstraZeneca website)</article-title>. <year>2020</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html">https://www.astra​zeneca.com/media​-centr​e/press​-relea​ses/2020/updat​e-on-phase​-iii-stren​gth-trial​-for-epano​va-in-mixed​-dysli​pidae​mia-13012​020.html</ext-link>. Accessed July 10, 2020.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="miscellaneous" id="jah35420-cit-0037"><string-name><surname>Chowdhury</surname><given-names>IN</given-names></string-name>. <article-title>Clinical review, NDA 202057, Vascepa/Icosapent Ethyl</article-title>. <year>2012</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057Orig1s000MedR.pdf">http://www.acces​sdata.fda.gov/drugs​atfda_docs/nda/2012/20205​7Orig​1s000​MedR.pdf</ext-link>. Accessed July 10, 2020.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0038"><string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Wu</surname><given-names>JHY</given-names></string-name>. <article-title>Omega‐3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2011</year>;<fpage>2047</fpage>–<lpage>2067</lpage>.<pub-id pub-id-type="pmid">22051327</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0039"><string-name><surname>Fioretto</surname><given-names>P</given-names></string-name>, <string-name><surname>Giaccari</surname><given-names>A</given-names></string-name>, <string-name><surname>Sesti</surname><given-names>G</given-names></string-name>. <article-title>Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus</article-title>. <source xml:lang="en">Cardiovasc Diabetol</source>. <year>2015</year>;<fpage>142</fpage>.<pub-id pub-id-type="pmid">26474563</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0040"><string-name><surname>Barnett</surname><given-names>AH</given-names></string-name>, <string-name><surname>Mithal</surname><given-names>A</given-names></string-name>, <string-name><surname>Manassie</surname><given-names>J</given-names></string-name>, <string-name><surname>Jones</surname><given-names>R</given-names></string-name>, <string-name><surname>Rattunde</surname><given-names>H</given-names></string-name>, <string-name><surname>Woerle</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Broedl</surname><given-names>UC</given-names></string-name>. <article-title>Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en">Lancet Diabetes Endocrinol</source>. <year>2014</year>;<fpage>369</fpage>–<lpage>384</lpage>.<pub-id pub-id-type="pmid">24795251</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0041"><string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Stone</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>C</given-names></string-name>, <string-name><surname>Bittner</surname><given-names>V</given-names></string-name>, <string-name><surname>Criqui</surname><given-names>MH</given-names></string-name>, <string-name><surname>Ginsberg</surname><given-names>HN</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>AC</given-names></string-name>, <string-name><surname>Howard</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>MS</given-names></string-name>, <string-name><surname>Kris‐Etherton</surname><given-names>PM</given-names></string-name>, et al. <article-title>Triglycerides and cardiovascular disease</article-title>. <source xml:lang="en">Circulation</source>. <year>2011</year>;<fpage>2292</fpage>–<lpage>2333</lpage>.<pub-id pub-id-type="pmid">21502576</pub-id></mixed-citation>
              </ref>
              <ref id="jah35420-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0042"><string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Stroes</surname><given-names>ESG</given-names></string-name>. <article-title>FISHing for the miracle of eicosapentaenoic acid</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<fpage>89</fpage>–<lpage>90</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35420-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jah35420-cit-0043"><string-name><surname>Bays</surname><given-names>HE</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Braeckman</surname><given-names>RA</given-names></string-name>, <string-name><surname>Stirtan</surname><given-names>WG</given-names></string-name>, <string-name><surname>Soni</surname><given-names>PN</given-names></string-name>. <article-title>Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR Studies</article-title>. <source xml:lang="en">Am J Cardiovasc Drugs</source>. <year>2013</year>;<fpage>37</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">23325450</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
